IsoPlexis Uses Single-Cell Platform to Assess T Cell Activity in CAR-T Cancer Therapy – GenomeWeb
|
IsoPlexis Uses Single-Cell Platform to Assess T Cell Activity in CAR-T Cancer Therapy
GenomeWeb NEW YORK (GenomeWeb) – Single-cell omics firm IsoPlexis presented data at the American Association for Cancer Research annual meeting this week in Chicago demonstrating the ability of its platform to assess the activity of T cells used in adoptive cell … |
